Loading SEYAIND price...
Peers are the listed companies in the exchange's own industry group: Specialty Chemicals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Latest quarterIn the quarter to June 2026 (results filed 14 Aug 2026), sales was Rs 0.0 cr and the loss was Rs 0.7 cr against Rs 0.6 cr a year earlier.
- Sales fell 4 years running (Rs 64.4 cr in FY22 to Rs 0.0 cr in FY26).
- Reported a loss in FY24 and FY25 and FY26.
- Return on equity stayed under 10% from FY24 to FY26 (highest -0.4%).
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Over the last 17 results, the share rose on 3 and fell on 14, and moved by 3% or more on 13.
Q1 FY27: results filed 14 Aug 2026. The share went from its close on 13 Aug 2026 to its close on 17 Aug 2026 +1.46%.
Of every Rs 100 of sales in FY25, Rs 102 went on running costs, Rs 346 on depreciation; the year ended in a loss.
Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.
Per year, compounded, between financial years FY25 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.
| Measure | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales growthSales against the previous financial year. | - | -39.3% | -79.3% | -35.8% | - |
| Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales. | 12.6% | -39.1% | 46.9% | -1.9% | - |
| Net marginProfit after everything, per Rs 100 of sales. | -9.8% | -63.2% | -43.2% | -121% | - |
| ROEProfit as a percentage of shareholders' money (from the March balance sheet). | - | -3.0% | -0.4% | -0.8% | -0.5% |
| ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'. | - | -1.7% | -0.3% | -0.5% | -0.3% |
| Debt to equityBorrowings divided by shareholders' money. Lower is safer. | - | 0.93x | 0.93x | 0.94x | 0.94x |
Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).
At FY26 it owned Rs 1,605 Cr of assets. Its owners funded 51% of that and borrowings 48%.
From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.
In FY26 the business itself brought in Rs -17 Cr, and cash fell by Rs 0 Cr over the year.
Full financial year to 2026-03-31, from the company's cash flow statement.
Operating margin has gone from 12.6% to -1.9% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.
2019 paid Rs 1.50 per share, about Rs 13,021 on Rs 1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.
Insider trading data unavailable.
Announcements unavailable.
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.